Patients

Axial spondyloarthritis, including non-radiographic spondyloarthropathy, affects approximately 1% of the population and represents a group of chronic inflammatory diseases that are frequently diagnosed late, often three or more years after the onset of low back pain. In many patients, the disease initially presents as chronic inflammatory low back pain (SpA), with more specific clinical signs or imaging features emerging only over time. Axial spondyloarthritis is typically diagnosed in the second or third decade of life, after which patients generally require increased medical care for the remainder of their lives. Even with current therapies, disease progression often continues, frequently leading to fusion of the spine. In addition, patients with Axial spondyloarthritis are subject to multiple complications, each of which may require extensive and ongoing medical management. 

Low back pain lasting longer than three months, commonly referred to as non-specific low back pain (NSLBP), is among the most prevalent causes of disability worldwide, affecting up to 10% of the adult population at some point in life. This condition is termed “non-specific” because it is thought to arise from a variety of underlying causes. Importantly, however, approximately 10–15% of NSLBP is considered to be driven by inflammation, while about 85% is believed to have a mechanical basis. Distinguishing inflammatory back pain from mechanical back pain is highly desirable, as inflammatory back pain, when identified early, is more likely to respond well to anti-inflammatory therapy. 

KeyIn-1 is designed to support patients by helping clinicians better understand what is happening beneath the surface of chronic inflammation. By providing clearer insight into inflammatory activity from a simple blood test, KeyIn-1 can help guide earlier diagnosis, more informed treatment decisions, and more personalized care over time. This approach aims to reduce uncertainty, avoid unnecessary treatment delays, and support better long-term outcomes for patients living with chronic inflammatory disease.